VRDN

28.68

0.95% 0.27

Dopo l'orario di chiusura: 28.68

Viridian Therapeutics Inc (VRDN)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione Frazionamento azionario

Precedente Chiudi:

$28.41

Aprire:

$28.76

Volume 24 ore:

1.13M

Relative Volume:

0.81

Capitalizzazione di mercato:

$2.93B

Reddito:

$70.85M

Utile/perdita netta:

$-324.22M

Rapporto P/E:

-7.5345

EPS:

-3.8065

Flusso di cassa netto:

$-277.36M

1 W Prestazione:

+1.20%

1M Prestazione:

+2.80%

6M Prestazione:

+51.99%

1 anno Prestazione:

+81.40%

Intervallo 1D:

$28.55

$29.86

Intervallo di 1 settimana:

$27.63

$30.42

Portata 52W:

$9.90

$34.29

Viridian Therapeutics Inc Stock (VRDN) Company Profile

Nome

Viridian Therapeutics Inc

Settore

Healthcare (1116)

Industria

Biotechnology (621)

Telefono

617.272.4600

Indirizzo

221 CRESCENT STREET, WALTHAM

Dipendente

252

Cinguettio

Prossima data di guadagno

2024-11-11

Ultimi documenti SEC

VRDN's Discussions on Twitter

Compare VRDN vs VRTX, REGN, ARGX, ALNY, ONC

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
VRDN Viridian Therapeutics Inc	28.68	2.93B	70.85M	-324.22M	-277.36M	-3.8065
VRTX Vertex Pharmaceuticals Inc	469.34	119.23B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	745.77	78.84B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	700.45	43.35B	4.16B	1.29B	734.26M	19.59
ALNY Alnylam Pharmaceuticals Inc	313.41	41.57B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	284.05	31.51B	5.36B	287.73M	924.18M	2.5229

Viridian Therapeutics Inc Stock (VRDN) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-12-10	Reiterato	Wedbush	Outperform
2025-12-03	Iniziato	William Blair	Outperform
2025-11-24	Iniziato	Truist	Buy
2025-08-25	Ripresa	Jefferies	Buy
2024-12-19	Downgrade	Wells Fargo	Overweight → Equal Weight
2024-11-25	Iniziato	TD Cowen	Buy
2024-09-11	Reiterato	Needham	Buy
2024-06-11	Iniziato	Wolfe Research	Outperform
2024-06-06	Iniziato	Goldman	Buy
2024-05-09	Downgrade	B. Riley Securities	Buy → Neutral
2024-05-09	Downgrade	Ladenburg Thalmann	Buy → Neutral
2023-06-14	Iniziato	BTIG Research	Buy
2023-06-14	Ripresa	Credit Suisse	Outperform
2023-05-30	Iniziato	RBC Capital Mkts	Outperform
2023-04-17	Iniziato	Wells Fargo	Overweight
2023-03-30	Iniziato	Stifel	Buy
2022-12-19	Iniziato	Cowen	Outperform
2022-12-19	Iniziato	Needham	Buy
2022-12-16	Iniziato	Credit Suisse	Outperform
2022-12-01	Iniziato	H.C. Wainwright	Buy
2022-06-23	Iniziato	B. Riley Securities	Buy
2021-11-18	Iniziato	SVB Leerink	Outperform
2021-10-12	Iniziato	Evercore ISI	Outperform
2021-01-25	Iniziato	Ladenburg Thalmann	Buy

Mostra tutto

Viridian Therapeutics Inc Borsa (VRDN) Ultime notizie

06:28 AM

Viridian Therapeutics Stock Up 75%, but One Fund Just Sold Off Its $69 Million Stake - AOL.com

06:28 AM

Mar 12, 2026

How Viridian Therapeutics Inc. stock responds to policy changesMarket Growth Report & Advanced Technical Analysis Signals - mfd.ru

Mar 12, 2026

Mar 11, 2026

Earnings Beat: Is Viridian Therapeutics Inc subject to activist investor interestGap Up & Low Risk Investment Opportunities - baoquankhu1.vn

Mar 11, 2026

VRDN: Wedbush Reiterates 'Outperform' Rating with $44 Target | V - GuruFocus

Mar 11, 2026

Wedbush Reaffirms Outperform Rating for Viridian Therapeutics (NASDAQ:VRDN) - MarketBeat

Mar 11, 2026

Viridian Therapeutics, Kissei Pharmaceutical Partner for Japanese Development of Thyroid Eye Disease Therapies, Securing $70M Upfront - MSN

Mar 11, 2026

(VRDN) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily

Mar 11, 2026

Mar 10, 2026

RBC Capital lowers its price target on Viridian Therapeutics, Inc. (VRDN) to $42 and maintains an outperform rating - MSN

Mar 10, 2026

Mar 09, 2026

Viridian Therapeutics (VRDN) CFO amends Form 4 for tax-share disposal - Stock Titan

Mar 09, 2026

Viridian Therapeutics (VRDN) legal chief updates tax share disposition - Stock Titan

Mar 09, 2026

Viridian Therapeutics (NASDAQ: VRDN) CEO amends Form 4 tax sale - Stock Titan

Mar 09, 2026

Analyst Upgrade: Can Viridian Therapeutics Inc be the next market leader2026 Weekly Recap & Consistent Profit Alerts - baoquankhu1.vn

Mar 09, 2026

Viridian Therapeutics at Leerink Conference: Eyeing Market Expansion By Investing.com - Investing.com Canada

Mar 09, 2026

Mar 07, 2026

Published on: 2026-03-07 18:48:40 - baoquankhu1.vn

Mar 07, 2026

Viridian Therapeutics (NASDAQ:VRDN) Downgraded to "Sell" Rating by Wall Street Zen - MarketBeat

Mar 07, 2026

Mar 06, 2026

Volume Recap: Can Viridian Therapeutics Inc withstand a market correctionJuly 2025 Summary & Low Risk Entry Point Guides - baoquankhu1.vn

Mar 06, 2026

Can Viridian Therapeutics Inc stock double in the next yearEarnings Beat & Community Trade Idea Sharing Platform - baoquankhu1.vn

Mar 06, 2026

RBC Capital Lowers Its Price Target on Viridian Therapeutics, Inc. (VRDN) to $42 and Maintains an Outperform Rating - Finviz

Mar 06, 2026

Vanguard Group Inc. Has $93.48 Million Holdings in Viridian Therapeutics, Inc. $VRDN - MarketBeat

Mar 06, 2026

Mar 05, 2026

Retinitis Pigmentosa Market: Strong Pharma Growth Forecast Through 2034 – DelveInsight | SparingVision SAS, ProQR Therapeutics NV, Viridian Therapeutics Inc, 4D Molecular Therapeutics Inc - Barchart.com

Mar 05, 2026

Propel Bio Management LLC Makes New Investment in Viridian Therapeutics, Inc. $VRDN - MarketBeat

Mar 05, 2026

Mar 04, 2026

Viridian Therapeutics at TD Cowen Conference: Strategic Moves in TED Treatment By Investing.com - Investing.com South Africa

Mar 04, 2026

Viridian Therapeutics at TD Cowen Conference: Strategic Moves in TED Treatment - Investing.com Australia

Mar 04, 2026

[144] Viridian Therapeutics, Inc.DE SEC Filing - Stock Titan

Mar 04, 2026

VRDN (NASDAQ: VRDN) Form 144: proposed sale of 1,675 vested shares - Stock Titan

Mar 04, 2026